A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe

Inclusion Criteria:

• Adults aged 19 years or older

• Patients diagnosed with hypercholesterolemia who have been stably treated withatorvastatin or rosuvastatin monotherapy for at least 3 months, and for whomswitching to fixed-dose combination pitavastatin/ezetimibe has been clinicallydecided

• Patients with available clinical laboratory test results related to efficacy andsafety (TC, TG, HDL-C, LDL-C, AST, ALT, Cr/eGFR) within 12 months prior to switchingto fixed-dose combination pitavastatin/ezetimibe (no changes in statin regimen ordosage during that period)

• Individuals (or their legally authorized representatives) who voluntarily providewritten informed consent to participate in the study

Exclusion Criteria:

• Known hypersensitivity or history of hypersensitivity to any component of theinvestigational product

• Patients with active liver disease or persistent, unexplained elevations ofaminotransferase levels

• Patients with severe hepatic impairment, biliary obstruction, or cholestasis

• Patients currently receiving cyclosporine treatment

• Patients diagnosed with myopathy

• Pregnant or breastfeeding women, or women who may be pregnant

• Patients with genetic disorders such as galactose intolerance, Lapp lactasedeficiency, or glucose-galactose malabsorption

• Any patient who, in the opinion of the investigator, is deemed unsuitable for studyparticipation